A new analysis suggests that the cardiovascular benefits of Novo Nordisk's weight loss drug Wegovy are not tied to the amount of weight lost. If half of American adults with obesity took Wegovy with a 40% rebate, it could cost over $400 billion annually, potentially surpassing total retail prescription drug spending in 2022. Senator Sanders warns that the high price of Wegovy and similar drugs could strain Medicare and the healthcare system due to greed. Users of Wegovy may maintain weight loss for up to 4 years, with an average of 10% body weight reduction. A long-term trial indicates that initial weight loss with Wegovy plateaus after about 65 weeks. Novo Nordisk, the maker of Wegovy, is praised for its success in bringing the drug to market.
Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug. https://t.co/tZVFYT5zeh
Clinical researchers recently published a long-term study evaluating Novo Nordisk's (NYSE: $NVO) obesity drug, Wegovy. According to Visible Alpha consensus, analysts estimate Wegovy will reach $22.5 billion in revenue in 2030. Dive into the analysis. https://t.co/SvmXe7oDol
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, maker of the weight loss drug Wegovy, is tops, according to a new analysis. #STATBreakthrough https://t.co/ud9F9dTHJe
A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then hit a plateau or “set point.” https://t.co/rXanUcPGxv
People with heart problems who took the weight loss drug Wegovy maintained an average weight loss of 10% of their body weight 4 years after starting the drug. https://t.co/TFEjtcNzaM https://t.co/c3BpYv0udL
Wegovy users may keep the weight off for 4 years, drug's maker says @mallikamarshall reports https://t.co/OD96p2PVjb
Today’s report makes it crystal clear: The outrageously high price of Wegovy and other weight loss drugs have the potential to bankrupt Medicare and our entire health care system. The reason? Greed. The United States government cannot allow that to happen. https://t.co/ML6haWgVld
“Assuming a 40% rebate on Wegovy, Sanders’ team concluded that if half of American adults with obesity took the drug for weight-loss, it could cost more than $400 billion a year — surpassing what Americans spent on all retail prescription drugs in 2022.” https://t.co/AvL2INe2Ip
The cardiovascular benefits of Novo Nordisk’s blockbuster weight loss drug Wegovy are not dependent on the amount of weight patients lost, according to a new analysis. https://t.co/yCblw4SZiA